X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4864) 4864
Publication (445) 445
Newsletter (207) 207
Book Review (58) 58
Magazine Article (40) 40
Book Chapter (39) 39
Newspaper Article (36) 36
Dissertation (9) 9
Book / eBook (3) 3
Conference Proceeding (2) 2
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3882) 3882
lipodystrophy (2858) 2858
male (2113) 2113
female (2009) 2009
adult (1751) 1751
hiv infections - drug therapy (1652) 1652
index medicus (1445) 1445
middle aged (1371) 1371
infectious diseases (1156) 1156
hiv (1143) 1143
hiv infections - complications (862) 862
insulin-resistance (841) 841
antiretroviral therapy (811) 811
insulin resistance (766) 766
protease inhibitors (743) 743
immunology (741) 741
risk factors (665) 665
anti-hiv agents - adverse effects (658) 658
antiretroviral therapy, highly active - adverse effects (633) 633
endocrinology & metabolism (585) 585
lipodystrophy - chemically induced (582) 582
hiv infection (560) 560
anti-hiv agents - therapeutic use (535) 535
highly active antiretroviral therapy (499) 499
active antiretroviral therapy (446) 446
virology (445) 445
care and treatment (442) 442
research (439) 439
animals (428) 428
hiv patients (417) 417
health aspects (405) 405
adolescent (392) 392
antiretroviral therapy, highly active (381) 381
hiv protease inhibitors - adverse effects (364) 364
lipoatrophy (363) 363
drug therapy (361) 361
treatment outcome (360) 360
aged (359) 359
hyperlipidemia (359) 359
cross-sectional studies (352) 352
child (351) 351
hiv-associated lipodystrophy syndrome - chemically induced (344) 344
aids (343) 343
adipose-tissue (336) 336
human-immunodeficiency-virus (336) 336
pharmacology & pharmacy (335) 335
antiviral agents (331) 331
diabetes (327) 327
prevalence (320) 320
body composition (311) 311
reverse-transcriptase inhibitors (297) 297
therapy (297) 297
hiv-1 (296) 296
hiv infections - metabolism (286) 286
medicine, general & internal (275) 275
obesity (273) 273
drug therapy, combination (271) 271
reverse transcriptase inhibitors - adverse effects (271) 271
hiv-associated lipodystrophy syndrome - drug therapy (270) 270
insulin (269) 269
infected patients (266) 266
lipodystrophy - etiology (263) 263
lipodystrophy - drug therapy (262) 262
lipodystrophy - complications (261) 261
human immunodeficiency virus--hiv (260) 260
leptin (252) 252
physiological aspects (248) 248
body-composition (246) 246
hiv-infected patients (240) 240
metabolic syndrome (235) 235
dyslipidemia (234) 234
metabolism (232) 232
body mass index (231) 231
cd4 lymphocyte count (231) 231
article (230) 230
mice (230) 230
hiv protease inhibitors - therapeutic use (226) 226
prospective studies (221) 221
diabetes-mellitus (220) 220
disease (217) 217
adipose tissue - metabolism (214) 214
medicine & public health (214) 214
hiv-1-infected patients (213) 213
adipose tissue - pathology (211) 211
mutation (209) 209
analysis (208) 208
glucose (208) 208
hiv infections - blood (207) 207
reverse transcriptase inhibitors - therapeutic use (203) 203
haart (202) 202
risk (201) 201
adipose tissue (200) 200
risk-factors (200) 200
cohort studies (195) 195
lipodystrophy syndrome (195) 195
viral load (192) 192
lipids - blood (191) 191
lipodystrophy - metabolism (190) 190
diagnosis (189) 189
triglycerides - blood (188) 188
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4737) 4737
French (128) 128
German (92) 92
Spanish (91) 91
Portuguese (51) 51
Italian (19) 19
Polish (18) 18
Russian (15) 15
Japanese (9) 9
Chinese (8) 8
Danish (7) 7
Czech (4) 4
Dutch (3) 3
Korean (3) 3
Romanian (3) 3
Serbian (2) 2
Swedish (2) 2
Bulgarian (1) 1
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 09/2004, Volume 351, Issue 11, pp. 1106 - 1118
  Despite a large need for new hypoglycemic therapies, given the epidemic of type 2 diabetes, very few agents have been introduced during the past 20 years.... 
POLYCYSTIC-OVARY-SYNDROME | MEDICINE, GENERAL & INTERNAL | ACTIVATED RECEPTOR-GAMMA | HAART-ASSOCIATED LIPODYSTROPHY | HEPATIC FAT-CONTENT | IMPROVES GLYCEMIC CONTROL | ADIPOSE-SPECIFIC PROTEIN | INSULIN-RESISTANCE | PPAR-GAMMA | TYPE-2 DIABETES-MELLITUS | CORONARY-ARTERY-DISEASE | Proteins | Insulin resistance | Diabetes | Insulin | Rodents
Journal Article
Journal Article
Journal Article
AIDS (London, England), ISSN 0269-9370, 2003, Volume 17, Issue 8, pp. 1179 - 1193
Journal Article
Drugs, ISSN 0012-6667, 09/2013, Volume 73, Issue 13, pp. 1431 - 1450
In the late 1990s, reports of unusual changes in body fat distribution named 'lipodystrophy' (LD) began to appear in HIV patients mitigating the enormous... 
REVERSE-TRANSCRIPTASE INHIBITORS | ONCE-DAILY DOLUTEGRAVIR | NAIVE HIV-1-INFECTED PATIENTS | ADIPOSE-TISSUE DISTRIBUTION | CO-FORMULATED ELVITEGRAVIR | X-RAY ABSORPTIOMETRY | PHARMACOLOGY & PHARMACY | TOXICOLOGY | QUALITY-OF-LIFE | ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | RANDOMIZED COMPARATIVE TRIAL | PATIENTS 96-WEEK EFFICACY | HIV-Associated Lipodystrophy Syndrome - therapy | HIV-Associated Lipodystrophy Syndrome - prevention & control | Darunavir | Humans | Antiretroviral Therapy, Highly Active - adverse effects | HIV Integrase Inhibitors - administration & dosage | Oligopeptides - adverse effects | Reverse Transcriptase Inhibitors - administration & dosage | Oligopeptides - therapeutic use | Pyrrolidinones - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Pyridines - adverse effects | Aging | Atazanavir Sulfate | HIV-Associated Lipodystrophy Syndrome - etiology | Nucleosides - metabolism | Reverse Transcriptase Inhibitors - therapeutic use | Raltegravir Potassium | Pyridines - therapeutic use | HIV Protease Inhibitors - adverse effects | Anti-Retroviral Agents - therapeutic use | Pyrrolidinones - adverse effects | Adiposity - drug effects | Pyridines - administration & dosage | Anti-Retroviral Agents - adverse effects | Pyrrolidinones - therapeutic use | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Randomized Controlled Trials as Topic | Sulfonamides - therapeutic use | HIV Integrase Inhibitors - adverse effects | Anti-Retroviral Agents - administration & dosage | HIV Integrase Inhibitors - therapeutic use | Sulfonamides - adverse effects | HIV Infections - drug therapy | HIV-Associated Lipodystrophy Syndrome - metabolism | Oligopeptides - administration & dosage | HIV Infections - physiopathology | Drug Combinations | Sulfonamides - administration & dosage
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2003, Volume 349, Issue 21, pp. 1993 - 2003
Journal Article
Journal Article